BlueGENEs

Stages

1. 1.
   Optogenetic switch and response system design(library_design)

   The abstract states that BlueGENEs comprises a blue light-responsive gene switch, a synthetic response promoter, and selection strategies, indicating an upfront design stage to create an optimized optogenetic system for stable mammalian use.

   Selection: Design of optimized blue light-responsive gene switches, synthetic response promoter, and selection strategies for broad use scenarios.

2. 2.
   Stable genomic engineering into human cells(library_build)

   Stable genomic engineering is described as necessary to support long-term cultivation and high response resolution, and targeted insertion is presented as a way to avoid disruptive random delivery effects.

   Selection: Generation of stable human cell lines including precision engineering into the AAVS1 safe harbor locus.

3. 3.
   Selection strategy deployment(selection)

   The abstract explicitly states that BlueGENEs includes selection strategies, implying a stage used to obtain or maintain engineered cell lines suitable for downstream applications.

   Selection: Selection strategies serving broad use scenarios.

4. 4.
   Functional application characterization in human cell lines(functional_characterization)

   The paper demonstrates that engineered cell lines can control multiple biologically relevant outputs, showing that the switch architecture functions in intended tissue engineering contexts.

   Selection: Demonstration of optical control over apoptotic cell fate, 3D tissue formation, and signals promoting cytoskeletal remodeling.

5. 5.
   Bioprinting integration validation(confirmatory_validation)

   The abstract presents bioprinting integration as a downstream demonstration of practical utility for de novo or patient-derived in vitro model systems.

   Selection: Demonstration that optogenetic cells integrate with bioprinting technologies.

Steps

1. 1.
   Design optimized BlueGENEs componentsengineered optogenetic switch system

   Create an optimized blue light-responsive gene switch system with a synthetic response promoter and selection strategies.

   The abstract first introduces development of BlueGENEs as the engineered system before describing stable cell line generation and applications.

2. 2.
   Install BlueGENEs into human cells using designer endonuclease and phage integrasegenetic payload being genomically installed

   Generate stable human cell lines including precision engineering into the AAVS1 safe harbor locus.

   Stable genomic engineering is required to support long-term cultivation and high response resolution, so installation into cells follows system design.

3. 3.
   Apply selection strategies to obtain usable engineered cell linesengineered system under selection

   Support broad use scenarios by selecting engineered cell lines suitable for downstream applications.

   Selection logically follows genomic engineering because the abstract describes selection strategies as part of the BlueGENEs platform for cell line generation.

4. 4.
   Test optical control of target cellular programsoptogenetic control system being functionally characterized

   Demonstrate optical control of apoptotic cell fate, 3D tissue formation, and signals promoting cytoskeletal remodeling.

   Functional testing follows generation of stable selected cell lines because it assesses whether the engineered system performs intended biological control tasks.

5. 5.
   Integrate optogenetic cells with bioprinting technologiesengineered optogenetic cells used in downstream platform integration

   Demonstrate compatibility with bioprinting technologies for in vitro model system synthesis.

   This is a downstream confirmatory application after functional cell-line validation, showing practical integration into tissue engineering workflows.